Young Kwang Chae

  • 1693 Citations
20072022
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Personalized Cancer Therapy, Precision Medicine, Early Phase Clinical Trials, First-in-Human Study, Novel Combination Cancer Therapy, Targeted therapy, Immunotherapy, Biomarker Study, Novel Drug Development, Novel Drug Delivery System, Adaptive Clinical Trials Design, Cell Signaling Pathway, Immune Checkpoint Pathway

Training Experience

2011Residency, Albert Einstein Medical Center
2014Fellowship, University of Texas/MD Anderson Cancer Center

Education/Academic qualification

MBA, Johns Hopkins University

… → 2007

MPH, Johns Hopkins University

… → 2007

MD, Seoul National University

… → 2002

Keywords

  • Oncology

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 5 Similar Profiles
Neoplasms Medicine & Life Sciences
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Hydroxymethylglutaryl-CoA Reductase Inhibitors Medicine & Life Sciences
Biomarkers Medicine & Life Sciences
T-Lymphocytes Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2013 2022

Research Output 2007 2019

1 Citation (Scopus)

A phase I dose-escalation study of veliparib combined with carboplatin and etoposide in patients with extensive-stage small cell lung cancer and other solid tumors

Atrafi, F., Groen, H. J. M., Byers, L. A., Garralda, E., Lolkema, M. P., Sangha, R. S., Viteri, S., Chae, Y. K., Ross Camidge, D., Gabrail, N. Y., Hu, B., Tian, T., Nuthalapati, S., Hoening, E., He, L., Komarnitsky, P. & Calles, A., Jan 15 2019, In : Clinical Cancer Research. 25, 2, p. 496-505 10 p.

Research output: Contribution to journalArticle

Open Access
Carboplatin
Small Cell Lung Carcinoma
Etoposide
Neoplasms
Disease Progression
3 Citations (Scopus)

Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti–PD-1/PD-L1 Therapy in Non–Small-Cell Lung Cancer

Chae, Y. K., Davis, A. A., Raparia, K., Agte, S., Pan, A., Mohindra, N. A., Villaflor, V. M. & Giles, F., Mar 1 2019, In : Clinical Lung Cancer. 20, 2, p. 88-96.e6

Research output: Contribution to journalArticle

Tumor Burden
Non-Small Cell Lung Carcinoma
DNA Repair
Ligands
Mutation

Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer

Chae, Y. K., Davis, A. A., Agte, S., Pan, A., Simon, N. I., Iams, W. T., Cruz, M. R., Tamragouri, K., Rhee, K., Mohindra, N. A., Villaflor, V. M., Park, W., Lopes, G. & Giles, F. J., Jun 1 2019, In : Oncologist. 24, 6, p. 820-828 9 p.

Research output: Contribution to journalArticle

Tumor Burden
Non-Small Cell Lung Carcinoma
DNA
Neoplasms
Programmed Cell Death 1 Receptor
DNA Mismatch Repair
Endometrial Neoplasms
Immunotherapy
Ligands
Neoplasms
1 Citation (Scopus)

Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions

Chae, Y. K. & Oh, M. S., Jan 1 2019, In : Journal of Thoracic Oncology. 14, 1, p. 16-24 9 p.

Research output: Contribution to journalReview article

Residual Neoplasm
Lung Neoplasms
DNA
Neoplasms
DNA Fingerprinting